Awakn Life Sciences to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Toronto, Ontario--(Newsfile Corp. - June 10, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn's Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright's Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday,...
2021-06-10 8:00 AM EDT
Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead
Toronto, Ontario--(Newsfile Corp. - April 27, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn's pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David...
2021-04-27 7:30 AM EDT
Awakn Life Sciences Inc. Announces Two Key Appointments to Its Board of Directors
Toronto, Ontario--(Newsfile Corp. - April 19, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction, announced today the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the Company's Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent board governance to Awakn.Stephen Page...
2021-04-19 9:17 AM EDT
Awakn Launches Digital Unit and Signs Agreement with the University of Exeter to Improve Addiction Treatment Through Artificial Intelligence and Big Data
London, United Kingdom--(Newsfile Corp. - April 12, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today launched 'Awakn Digital', a new unit focused on using advanced analytics to improve the effectiveness of Psychedelic-Assisted Psychotherapy in treating Addiction. Awakn deepened its partnership with the University of Exeter to apply the latest developments in...
2021-04-12 9:54 AM EDT
Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt
London, United Kingdom--(Newsfile Corp. - March 9, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced the acquisition of significant proprietary research data on next generation candidate MDMA and Ketamine molecules from Prof. David Nutt's Equasy Enterprises. In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research...
2021-03-09 7:00 AM EST
Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) Intervention Validated in a Phase II Clinical Trial
London, United Kingdom--(Newsfile Corp. - March 2, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced an exclusive license to use and deliver the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention, as validated in a Phase II clinical trial led by the University of Exeter.The KARE clinical research study, led by Prof....
2021-03-02 7:50 AM EST
Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial
London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD).Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy...
2021-02-19 8:59 AM EST
Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer
London, United Kingdom--(Newsfile Corp. - January 25, 2021) - Awakn Life Sciences Inc., a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of James Collins as Chief Operating Officer, effective January 2021.Collins joins from Accenture Strategy where he was a Managing Director (London) for several years, responsible for client relationship development, sales, delivery,...
2021-01-25 7:00 AM EST
Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice
Toronto, Ontario--(Newsfile Corp. - January 19, 2021) - Awakn Life Sciences Inc., a biotechnology company focused on research, development and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof. Celia Morgan, from Exeter University, as Head of Ketamine-Assisted Psychotherapy for the company's Alcohol Use Disorder (AUD) Practice; both...
2021-01-19 7:00 AM EST
Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awakn Life Sciences announced today the selection of contract research organization ('CRO'), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent ('Harmful Use') Alcohol Use Disorder ("AUD").Awakn's Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical...
2021-01-15 7:00 AM EST
Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences
Toronto, Ontario--(Newsfile Corp. - October 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Professor Celia Morgan to its Scientific Advisory Board (SAB).Celia Morgan is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. She is one Europe's leading Ketamine researchers & investigators and the academic lead for the Exeter Translational Addiction Partnership. Prof. Morgan's research focuses on examining both the benefits...
2020-10-02 9:00 AM EDT
Dr. Michael Mithoefer & Ann Mithoefer from MAPS Join AWAKN's Scientific Board
Toronto, Ontario--(Newsfile Corp. - September 24, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Dr. Michael Mithoefer and Ann Mithoefer to its Scientific Advisory Board (SAB). Dr. Mithoefer, Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MPBC), has, has worked with MAPS since 2000, while Ann Mithoefer, a registered Nurse and Lead MDMA-Assisted Psychotherapy PTSD Investigator at MAPS, has worked...
2020-09-24 12:06 PM EDT
AWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Studies Across Europe & North America
Toronto, Ontario--(Newsfile Corp. - September 8, 2020) - AWAKN Life Sciences Inc ("AWAKN"), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division.AWAKN's purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and Practitioner Training. AWAKN's Commercial...
2020-09-08 8:00 AM EDT
Dr. Matthew Johnson Joins AWAKN Life Sciences
Toronto, Ontario--(Newsfile Corp. - September 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Dr. Mathew Johnson, Ph.D, to its Scientific Advisory Board (SAB).Dr. Johnson is one of the world's most published scientists on the human effects of psychedelics. He has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior through his role of Professor of Psychiatry and Behavioral Sciences at Johns Hopkins...
2020-09-02 3:08 PM EDT
AWAKN Life Sciences Partners with Drug Science in the UK
Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - AWAKN Life Sciences Inc ("AWAKN"), the psychedelic healthcare company focused on the UK and European markets, announced the new partnership to coincide with Drug Science's inaugural Psychedelics Working Group meeting that took place this week on 14th July 2020.Founded in 2010 by Professor David Nutt, Drug Science works to provide evidence for widespread application of psychedelic drugs within public health models. Its aim is to break the...
2020-07-16 8:00 AM EDT
Professor David Nutt Joins AWAKN Life Sciences
Toronto, Ontario--(Newsfile Corp. - July 7, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Professor David Nutt as Chairman of its newly formed Scientific Advisory Board (SAB). Professor David Nutt is a world renowned neuroscientist, leading global authority on drug policy reform and former chief drug advisor to the UK government. He serves as the Edmond J. Safra Professor of Neuropsychopharmacology and director of the neuropsychopharmacology unit in the...
2020-07-07 7:57 AM EDT
Psychedelic Medical Start-Up AWAKN Life Sciences Enters the UK Market with Dr. Ben Sessa
Toronto, Ontario--(Newsfile Corp. - June 18, 2020) - AWAKN Life Sciences Inc. ("AWAKN"), has signed a binding investment agreement to acquire a controlling interest in Mandala Therapy Limited, the UK based psychedelic clinical practice run by acclaimed author, researcher and consultant psychiatrist, Dr. Ben Sessa. Dr. Sessa will become AWAKN's Chief Medical Officer and will open the UK's first psychedelic-assisted psychotherapy clinic over the coming months. Under his leadership, AWAKN...
2020-06-18 9:00 AM EDT